Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of U3-1565 in Japanese Subjects with Advanced Solid Malignant Tumors
jRCT2080221445Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of U3-1565 in Non-hematologic malignancy, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety and tolerability of U3-1565.
02
Drugs
U3-1565
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080221445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221445.